Drug major Ranbaxy Laboratories Ltd, which has completed two decades of operations in Russia, is mulling to expand its product portfolio to induct value-added and innovator products from parent company, Daiichi Sankyo.

“Over years, Ranbaxy has established itself as a preferred generic pharmaceutical company in Russia. In coming years, we look at further expanding our product portfolio to include value-added and innovator products from our parent company, Daiichi Sankyo,” Aman Khanna, Country Head - Russia, Ranbaxy said in a statement here.

The company has completed 20 successful years in Russia and working closely in partnership with regional governments in line with Russia Pharma, 2020 Healthcare Plan, Khanna said.

The company has already grown to become a No.1 player with a market share of 15.4 per cent in represented market segment in Russia.

Ranbaxy has operations in 56 regions in Russia and has built strong equity with its customers. The company has a portfolio of products covering anti-infective, cold, pain management, cardiovascular, diabetology, central nervous system, urology and dermatology segments, the statement said.

The company has registered 51 drugs in the Russian Federation and commercialised 72 SKU’s. Ranbaxy’s leading brands in Russia includes Ketanov, Coldact, Faringosept, Cifran, Pylobact and Fenules so far, the release said.

“We remain committed to the Russian market and will continue to operate from the paradigm of quality and patients First,” Ranbaxy Managing Director and CEO, Arun Sawhney said.

The Russian pharmaceutical market is estimated at around $20 billion and is growing at a CAGR of around 11 per cent. The retail/out-of-pocket market contributes around 66 per cent to the total market.

Related Topics
comment COMMENT NOW